Cutaneous melanoma

This study tests whether adding an experimental drug (CMP-001) to the immunotherapy pembrolizumab can better shrink melanoma tumors before surgery and help prevent them from coming back. About 60 adults with stage III or recurrent melanoma that can be surgically removed will rece…

This study tests whether adding tocilizumab (a drug used for arthritis) to standard immunotherapy can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive all three drugs. The goal is to see if the combina…

This early-phase study tests whether 30 minutes of moderate exercise (like walking or cycling) right before standard immunotherapy can improve treatment for certain skin cancers (melanoma, squamous cell carcinoma, Merkel cell carcinoma). About 22 adults will exercise before each …

This phase 2 trial compares two ways of taking the targeted drugs dabrafenib and trametinib for advanced BRAF-mutant melanoma: continuously versus with planned breaks. About 280 people with stage III or IV melanoma that cannot be surgically removed are participating. The goal is …

This study looks at whether doctors can safely stop standard anti-PD-1 immunotherapy early in people with advanced melanoma that cannot be surgically removed. By using PET/CT scans and tumor biopsies as guides, the goal is to reduce treatment side effects and burden without harmi…

This early-phase trial tested the safety and best dose of two drugs—riluzole and sorafenib—given together to people with advanced solid tumors or melanoma that had spread and stopped responding to standard treatments. The goal was to find the highest safe dose and see if the comb…

This phase II trial tests whether adding a growth factor (GM-CSF) to the immunotherapy drug ipilimumab helps people with advanced melanoma live longer. About 245 patients with stage III or IV melanoma that cannot be surgically removed are randomly assigned to get ipilimumab alone…

This phase II trial is testing the drug dinaciclib in 72 people with stage IV melanoma that has spread. The drug works by blocking enzymes that help cancer cells grow. Researchers are looking at side effects and whether it helps patients live longer or slows tumor growth.

This early-phase trial tests two drugs together—MK-2206 and hydroxychloroquine—in people with advanced solid tumors, melanoma, kidney, or prostate cancer. The goal is to find the safest dose and see how the combination affects cancer cell growth. About 62 participants will take b…

This phase 3 trial tests whether the immunotherapy drug ipilimumab is better than high-dose interferon alfa-2b at preventing melanoma from coming back in patients whose cancer was removed by surgery. Over 1,600 people with high-risk stage III or IV melanoma took part. The study m…

This phase 2 trial is testing whether adding a personalized mRNA cancer vaccine (mRNA-4157) to the immunotherapy drug pembrolizumab can better prevent melanoma from coming back after surgery compared to pembrolizumab alone. The study involves 267 people with high-risk melanoma th…

This early-stage trial tests an experimental mRNA-based cancer vaccine (mRNA-4157) in 161 people with solid tumors. The vaccine is designed to train the immune system to attack cancer cells. Some participants receive the vaccine alone, while others get it with the immunotherapy d…

This study tests a new drug called INCB099280 in 73 people with advanced solid tumors who have not received immunotherapy before. The goal is to see if the drug can shrink tumors and to check for side effects. The study focuses on safety and how well the drug works in the short t…

This phase III trial compares the drug pembrolizumab (MK-3475) to the current standard treatments—high-dose interferon or ipilimumab—in 1,301 patients with high-risk melanoma that has been surgically removed. The goal is to see if pembrolizumab is better at preventing the cancer …

This phase III trial compares two sequences of treatment for advanced melanoma with a BRAF mutation. One group starts with immunotherapy (ipilimumab and nivolumab) followed by targeted therapy (dabrafenib and trametinib) if needed; the other group starts with targeted therapy the…

This study tests whether adding a drug called sargramostim to the standard immunotherapy combination of nivolumab and ipilimumab helps people with advanced melanoma live longer. About 600 patients with stage III or IV melanoma that cannot be surgically removed are participating. …

This phase II trial is testing whether a precise, high-dose radiation treatment called stereotactic radiosurgery can control melanoma that has spread to more than three spots in the brain. The study includes 49 patients and also checks whether this approach helps preserve memory …

This study tests a combination of three drugs—dabrafenib, trametinib, and navitoclax—in people with BRAF mutant melanoma or other solid tumors that have spread or can't be removed by surgery. The goal is to find the best dose and see how well the drugs shrink tumors. About 75 adu…

This study tested two targeted drugs, dabrafenib and trametinib, given before and after surgery in 58 people with stage III melanoma that has a BRAF gene mutation. The goal was to shrink tumors before surgery and kill any remaining cancer cells afterward. The approach aims to imp…

This phase 3 trial is testing whether the immunotherapy drug nivolumab (Opdivo) can prevent melanoma from coming back in people who have had their stage IIB/C melanoma completely removed. About 790 adults and children are randomly assigned to receive either nivolumab or a placebo…

This trial investigates whether combining atezolizumab (a drug that boosts the immune system) with bevacizumab (a drug that blocks blood vessel growth) can shrink tumors in people with advanced melanoma that cannot be removed by surgery or has spread. The study focuses on patient…

This phase II trial studies whether giving the immunotherapy drug pembrolizumab both before and after surgery is more effective than giving it only after surgery for patients with stage III-IV high-risk melanoma. About 313 participants will be randomly assigned to one of two trea…

This early-stage study tests whether a mix of three drugs—tacrolimus, nivolumab, and ipilimumab—can shrink or control certain skin cancers in people who have had a kidney transplant. The main goal is to see if the cancer responds without causing the body to reject the transplante…

This trial investigates whether adding propranolol, a beta-blocker typically used for heart conditions, can enhance the effects of the immunotherapy drug pembrolizumab in people with advanced melanoma that cannot be removed by surgery. The study includes two phases: first to find…

This study tests a new oral drug called LNS8801, alone or combined with the immunotherapy pembrolizumab (Keytruda), in up to 200 adults with advanced solid tumors that have spread. The goal is to find a safe dose and see if the drug shrinks tumors. It is an early-stage trial, so …

This trial investigates a new type of immunotherapy for people with advanced cancers that carry a specific marker called NY-ESO-1. Researchers take a patient's own T cells, modify them in the lab to better recognize and attack cancer cells, and then infuse them back. The study al…

This early-stage study tests a new drug called IOA-244 in about 210 adults with advanced or metastatic cancers like lung cancer, melanoma, and lymphoma. The main goal is to see if the drug is safe and tolerable, both alone and combined with other treatments. Researchers also chec…

This trial investigates whether adding metformin, a common diabetes drug, to the immunotherapy pembrolizumab (Keytruda) can improve treatment for people with advanced melanoma. The study focuses on reversing metabolic problems inside tumors that may weaken immune cells. Participa…

This Phase II study tested a combination of two drugs—peginterferon alfa-2b and temozolomide—in 29 children with high-risk melanoma that had spread or come back. The main goal was to see how well the tumors shrank and to check for side effects. The study also looked at how long c…

This Phase 2 trial tests whether combining bevacizumab (Avastin) with atezolizumab (Tecentriq), with or without cobimetinib (Cotellic), can shrink or control melanoma that has spread to the brain. The study enrolls 29 adults with untreated brain metastases who are not taking ster…

This phase II trial is testing two different three-drug combinations in people with advanced BRAF-mutated melanoma that has spread or cannot be removed by surgery. One group receives nivolumab (immunotherapy) plus dabrafenib and trametinib (targeted therapy); the other receives n…

This early-phase trial is testing whether taking high-dose vitamin B5 (pantothenic acid) can help standard immunotherapy work better for people with advanced melanoma that cannot be surgically removed. The study includes 12 participants who have not had prior treatment for their …

This study tests whether a two-drug combination can help the immune system attack ovarian cancer that has returned after standard treatments. The drugs are E7777, which removes certain immune cells that block the body's defenses, and pembrolizumab, which reactivates cancer-fighti…

This early-phase trial tests the safety of combining two cancer drugs, nivolumab and cabozantinib, in people with HIV who have advanced solid tumors. Only 8 participants were enrolled. The goal is to see if the combination is safe and can shrink or stabilize tumors.

This phase 2 trial studies a combination of two immunotherapy drugs—talimogene laherparepvec (T-VEC) and pembrolizumab—in 43 adults with advanced melanoma that has worsened despite prior anti-PD1/L1 therapy. T-VEC is a modified virus that infects and kills cancer cells while also…

This pilot study tested whether adding low-dose radiation (brachytherapy) to standard immunotherapy could help shrink tumors in people with advanced melanoma, kidney cancer, or urothelial cancer. Only 5 participants were enrolled, and the main goal was to see how many responded t…

This early-phase trial is testing whether adding an experimental drug called VX15/2503 to standard immunotherapies (ipilimumab or nivolumab) can help treat stage IIIB-D melanoma that can be removed by surgery. About 41 participants will receive the drug combination before surgery…

This early-phase trial is testing a new drug called NTX-1088, which targets a protein on cancer cells, either alone or combined with the immunotherapy pembrolizumab. The study involves 90 people with advanced solid tumors that have spread or cannot be removed. The main goals are …

This study planned to test whether adding surgery, radiation, or electrochemotherapy could help control melanoma tumors that did not shrink with encorafenib + binimetinib combination therapy. It was designed for adults with BRAF-mutated melanoma who had been on the drugs for at l…

This phase II trial tests two drugs, pembrolizumab and lenvatinib, given before surgery to people with stage III melanoma that can be removed. The goal is to see if the combination can shrink or eliminate the tumor before the operation. Twenty-one participants will receive the dr…

This early-phase trial tests whether giving patients with advanced melanoma immune cells that have been genetically modified to resist tumor-suppressing signals can help fight the cancer. The modified T-cells are given along with high-dose Interleukin-2, a drug that boosts immune…

This phase 2 trial is testing whether giving two immunotherapy drugs, nivolumab and ipilimumab, before surgery can shrink stage III melanoma tumors and prevent the cancer from returning. The 28 participants will also receive an experimental PET scan that images immune cells to se…

This phase 2 trial is testing a combination of two immunotherapy drugs, zimberelimab and domvanalimab, in 8 adults with melanoma that stopped responding to PD-1 inhibitors. The goal is to see if the combination can shrink tumors or stop them from growing. The study is active but …

This early-phase trial tests a personalized vaccine called NeoVax, combined with an immune booster (CDX-301) and standard immunotherapy drugs (nivolumab or pembrolizumab), in 10 people with advanced melanoma. The goal is to see if the combination is safe and helps the immune syst…

This early-phase trial tests two drugs together—sonidegib and pembrolizumab—in 36 adults with advanced solid tumors that have spread. Sonidegib blocks a growth signal in cancer cells, while pembrolizumab helps the immune system attack the tumor. The main goals are to find the saf…

This phase 2 trial is testing several combinations of experimental drugs (LXH254, LTT462, trametinib, ribociclib) in 134 people with advanced melanoma that has a BRAF or NRAS mutation and has stopped responding to prior treatment. The main goal is to see if these combinations can…

This early-phase trial is testing whether the immunotherapy drug atezolizumab (Tecentriq) is safe to use before surgery in people with high-risk melanoma that hasn't spread. The study includes 20 participants and focuses on whether the treatment causes side effects that delay the…

This study tested whether giving the immunotherapy drug pembrolizumab after surgery helps prevent melanoma from returning in people with high-risk stage III melanoma. About 1,000 participants received either pembrolizumab or a placebo for up to a year. The main goal was to see if…

This early-phase trial tests a new three-drug combination for people with advanced BRAF-mutated melanoma that cannot be removed by surgery. The drugs are XL888 (an HSP90 inhibitor), vemurafenib, and cobimetinib. The main goal is to find the safest dose of XL888 when given with th…

This early-phase trial tests a new treatment for people with advanced melanoma that cannot be removed by surgery or has spread. The therapy uses a patient's own immune cells (tumor-infiltrating lymphocytes) grown in a lab and then given back along with a drug called ANV419 to hel…

This study tests a new two-drug combination (naporafenib + trametinib) in people with advanced NRAS-mutant melanoma that has already been treated. The goal is to see if the combo works better than standard treatments at slowing cancer growth and extending life. About 78 adults wi…

This early-stage trial tests whether giving a patient's own lab-grown tumor-fighting immune cells (Lifileucel) together with the immunotherapy drug pembrolizumab can safely shrink advanced melanoma. Only 2 people with stage IIIB-D or IV melanoma took part. The goal is to see if t…

This study looks at how well and how safely a combination of two cancer drugs, dabrafenib and trametinib, works when given after surgery to Chinese patients with stage III melanoma that has a specific gene change (BRAF V600). The goal is to see if the drugs help delay the cancer'…

This Phase 2 trial tests a genetically modified herpes virus (RP1) alone or with the immunotherapy drug nivolumab in people with advanced solid tumors, including melanoma, non-small cell lung cancer, and certain skin cancers. The study aims to see if the combination is safe and c…

This study tests an experimental drug called WTX-330 in 100 adults with advanced solid tumors or non-Hodgkin lymphoma that have not responded to standard treatments. The trial has two parts: first, finding the safest dose and schedule, then expanding to see how well the drug work…

This study tests giving two immunotherapy drugs (relatlimab and nivolumab) before surgery to people with high-risk stage II melanoma. The goal is to see if this combination can shrink or eliminate the tumor before it is removed. Twenty adults with residual disease after biopsy ar…

This early-phase study tested a new way of giving three drugs (encorafenib, binimetinib, and nivolumab) to people with advanced BRAF-mutant melanoma. Instead of taking the drugs every day, participants followed an on/off schedule to see if it could control the cancer while reduci…

This phase 2 trial is testing whether one year of pembrolizumab (an immunotherapy drug) works as well as the standard two-year course for people with advanced melanoma that cannot be surgically removed. The study involves 29 participants in Brazil's public health system and measu…

This early-phase study tests a new drug, DKY709, alone or with another drug (PDR001) in people with advanced solid tumors like lung cancer, melanoma, and breast cancer. The main goal is to find a safe dose and check for side effects. About 98 adults whose cancer worsened after st…

This phase 2 trial tests a new drug called botensilimab, alone or with another drug balstilimab, in 150 people with advanced melanoma that stopped responding to prior immunotherapy. The goal is to see if these drugs can shrink tumors or slow the cancer's growth. Researchers will …

This early-stage trial is testing a new drug called KFA115, either by itself or combined with the immunotherapy Keytruda (pembrolizumab), in 126 people with advanced cancers like lung, skin, kidney, and others. The main goal is to check safety and find the best dose. It is not ye…

This early-phase study tests a personalized vaccine (NeoVax) made from a patient's own tumor mutations, given alongside two immunotherapy drugs (nivolumab and ipilimumab) for advanced melanoma that cannot be surgically removed. The main goal is to check safety and find the right …

This early-stage trial aimed to test the safety of a new treatment called STIL101 for people with advanced pancreatic, colorectal, kidney, cervical cancer, or melanoma that has spread or cannot be removed. STIL101 is made from a patient's own immune cells taken from their tumor, …

This early-stage study tests a new treatment called T-Plex for people with advanced solid tumors (like head and neck, cervical, or melanoma) that haven't responded to standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab to recognize and…

This early-phase trial tests a new experimental antibody called BI-1607 alongside two existing immunotherapies (ipilimumab and pembrolizumab) in 35 people with advanced melanoma that has spread or cannot be removed. The goal is to see if the combination is safe and can shrink tum…

This study tests whether giving one or two immunotherapy drugs before surgery can shrink advanced melanoma (stage III or IV) that can be removed. About 48 adults with operable melanoma will receive either a single drug (dostarlimab) or a combination (dostarlimab plus cobolimab) b…

This study aimed to test a special vaccine made from modified melanoma cells to help the immune system fight remaining cancer in people with high-risk or low-burden melanoma. It was designed for patients with certain genetic markers and stages of melanoma. However, the study was …

This study tests whether adding a personalized mRNA vaccine (V940) to standard immunotherapy (pembrolizumab) can better prevent melanoma from returning in people with high-risk stage II–IV melanoma. About 1,089 participants who had their melanoma surgically removed will receive e…

This early-stage trial tests whether adding an experimental treatment (MB097) to the immunotherapy drug pembrolizumab is safe and shows signs of working in people with advanced melanoma that did not respond to standard anti-PD1 therapy. About 41 participants will receive the comb…

This study tests whether FYB206, a biosimilar (or copycat) of the cancer drug Keytruda, works similarly in the body. It involves 96 people with stage IIB/IIC or III melanoma that was completely removed by surgery. Participants receive either FYB206 or Keytruda, and researchers co…

This study tests an experimental oral drug called IMM-1-104, which blocks certain cancer-driving proteins. It is given alone or with standard chemotherapy to people with advanced solid tumors that have RAS mutations, including pancreatic, melanoma, and lung cancers. The trial aim…

This study tests whether adding a special stain called PRAME to standard tissue analysis helps surgeons remove early-stage melanoma more accurately. About 36 adults with stage 0 to IIc melanoma will have slow Mohs surgery, and their tissue will be checked both with and without PR…

This study is testing a gene signature (the Merlin Assay) to see if it can accurately predict whether melanoma has spread to nearby lymph nodes. Researchers are enrolling 1,820 newly diagnosed melanoma patients who are scheduled for a sentinel lymph node biopsy. The goal is to de…

This study tests whether atorvastatin, a widely used cholesterol medication, can prevent melanoma from returning or spreading in people who have had high-risk melanoma surgically removed. About 150 adults with stage IIA, IIB, or IIIA melanoma will receive either atorvastatin or a…

This early study tests whether short-term fasting (eating less than 200 calories per day for 3 days) before standard immunotherapy is safe and doable for people with advanced or metastatic skin cancer. Ten participants will receive their usual PD-1/PD-L1 inhibitor drugs along wit…

This phase 2 study looks at whether people with certain cancers (non-small cell lung cancer, kidney cancer, or melanoma) prefer getting the drug pembrolizumab as a quick shot under the skin instead of a longer IV infusion. About 147 participants will try both methods and then say…

This early-phase trial tested a special PET/CT imaging agent, Zirconium Zr 89 Crefmirlimab Berdoxam, to see if it can measure immune activity in tumors of patients with advanced melanoma. Six adults on immunotherapy plus hydroxychloroquine received scans before and after starting…

This study follows 126 melanoma survivors who are receiving immunotherapy after surgery. Researchers will track side effects and quality of life for up to 24 months. They will also collect blood samples to look for markers that might predict who gets side effects. The goal is to …

This study follows 250 young adult cancer survivors to see how their social relationships and physical activity change over time and how these factors affect their quality of life. Participants wear an activity tracker and complete surveys. The goal is to learn how to better supp…

This study looks at whether a fermented wheat germ supplement can help the immune system fight cancer better when taken with standard immunotherapy drugs. About 100 adults with advanced solid tumors (like lung, colon, or melanoma) will take the supplement alongside their usual tr…

This observational study collects extra tumor tissue from 416 people with various cancers (bladder, kidney, colorectal, head and neck, liver, lung, skin, endometrial) during routine biopsies. The goal is to develop and train a 'live tumor diagnostic platform' that can predict whe…

This study looks at whether Facebook groups can help young people diagnosed with melanoma (ages 18-39) and their close relatives do more skin exams and sun protection. About 1,160 participants will join either a melanoma-focused Facebook group or a healthy lifestyle Facebook grou…

This study looks at how a single dose of antibiotics given before melanoma surgery changes the bacteria in your gut. Researchers want to see if these changes affect how well the body responds to surgery and cancer treatment. The study involves 20 adults with early-stage melanoma …

This study checks if a blood test can find tiny bits of tumor DNA in people with melanoma before their surgery. About 296 adults with suspected skin cancer will give a blood sample before the tumor is removed. The goal is to see if this test can help doctors better understand a p…

This study follows 50 adults in the UK with advanced BRAF V600 mutation-positive melanoma who are starting treatment with encorafenib and binimetinib. Instead of a controlled trial, it observes how these drugs work in real-world settings, focusing on patients' quality of life ove…

This small pilot study is testing whether a 30-minute stationary bike ride on the same day as immunotherapy can help the treatment work better for people with skin cancers like melanoma. The study involves 12 patients and focuses on whether this exercise plan is practical and saf…

This study looks at how electrochemotherapy—using electric pulses to help chemotherapy enter tumor cells—changes the immune environment of melanoma skin tumors. Researchers want to see if it can turn 'cold' tumors (which don't respond well to immunotherapy) into 'hot' ones. Ten a…

This study looks at whether eating a high-fiber diet can change the gut bacteria of people with advanced melanoma who are receiving standard immunotherapy. About 50 participants will be randomly assigned to either a high-fiber or a healthy control diet for a set period. The main …

This study follows 10 children in the Netherlands who received ipilimumab for advanced melanoma that had spread or could not be removed. Researchers are looking at long-term side effects and patient characteristics. The goal is to understand how safe the drug is over time in youn…

This study aims to create a tool that can predict whether a cancer patient will benefit from their prescribed therapy. Researchers are analyzing blood samples from 10,000 people with advanced lung cancer or melanoma before and during treatment. The goal is to develop an algorithm…